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Abstract
Background: p63 is a member of the p53 transcription factor family. p63 is expressed from two promoters resulting
in proteins with opposite functions: the transcriptionally active TAp63 and the dominant-negative DNp63. Similar to p53,
the TAp63 isoforms induce cell cycle arrest and apoptosis. The DNp63 isoforms are dominant-negative variants opposing
the activities of p53, TAp63 and TAp73. To avoid unnecessary cell death accompanied by proper response to stress, the
expression of the p53 family members must be tightly regulated. NAD(P)H quinone oxidoreductase (NQO1) has recently
been shown to interact with and inhibit the degradation of p53. Due to the structural similarities between p53 and p63, we
were interested in studying the ability of wild-type and polymorphic, inactive NQO1 to interact with and stabilize p63. We
focused on TAp63c, as it is the most potent transcription activator and it is expected to have a role in tumor suppression.
Principal Findings: We show that TAp63c can be degraded by the 20S proteasomes. Wild-type but not polymorphic,
inactive NQO1 physically interacts with TAp63c, stabilizes it and protects it from this degradation. NQO1-mediated TAp63c
stabilization was especially prominent under stress. Accordingly, we found that downregulation of NQO1 inhibits TAp63c-
dependant p21 upregulation and TAp63c-induced growth arrest stimulated by doxorubicin.
Conclusions/Significance: Our report is the first to identify this new mechanism demonstrating a physical and functional
relationship between NQO1 and the most potent p63 isoform, TAp63c. These findings appoint a direct role for NQO1 in the
regulation of TAp63c expression, especially following stress and may therefore have clinical implications for tumor
development and therapy.
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Introduction
p63, a p53 family member, is expressed from two different
promoters generating two classes of proteins: TAp63, containing
the N-terminal transactivation (TA) domain, and DNp63, lacking
this domain. In addition, alternative splicing generates three
different C-termini: a, b and c. Given that the transactivation
activity resides in the protein’s N-terminus, TAp63 isoforms
function as transcription factors inducing cell cycle arrest and
apoptosis. TAp63c is the most potent transcription activator [1,2].
This isoform mimics p53 in culture and is capable of rescuing the
growth inhibitory function of p53, in p53-deficient cells [3,4].
These observations suggest that TAp63c has tumor-suppressive
properties analogous to p53. Supporting this notion is the fact that
p63 maps to a chromosome region often deleted in cancers [5].
Likewise, loss of TAp63 expression has been detected in several
cancers and has been associated with increased metastatic
potential [6–8]. In opposition to the TA isoforms, DNp63 protects
from apoptosis by directly competing for TAp63 target promoters
[1,9]. Over-expression of DNp63 isoforms observed in epithelial
cancers suggests that p63 can also act as an oncogene [10–12].
However, the predominant physiological role of p63 is in epithelial
development, as demonstrated by lack of epidermis and other
epithelia in p63-deficient mice [13].
To avoid unwanted cell death accompanied by proper response
to stress when needed, p53 family members have to be kept in
check. In unstressed cells, p53 activity is restrained via the RING-
type ubiquitin ligases Mdm2, Pirh2 and COP1. When cells
encounter genotoxic stress, p53 protein levels rapidly increase. This
correlates with a decrease in Mdm2 catalyzed poly-ubiquitylation
and an increase in a variety of other post-translational modifications
[14]. In contrast to the well-studied p53 protein, little is known
about the molecular mechanisms regulating p63. Some evidence
indicate that following genotoxic stress p63 is phosphorylated by
kinases such as p38 MAP kinase resulting in stabilization of the
TAp63 isoforms and detachment of DNp63a from p53-dependent
promoters followed by its accelerated degradation [15]. Recent
evidences have indicated a physical and functional relationship
between p63 and Itch/AIP4, a HECT ubiquitin ligase. The data
clearly indicate that all p63 isoforms are targeted by Itch for
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11401degradation[16]. In addition to the regulationof p63’s degradation,
crosstalk between p63 and proteins such as ASPP1/2 [17], PML
[18], Sp1/3 [19] and p300 [20] has been shown to lead to increased
transcriptional activity and stability of TAp63.
NAD(P)H quinone oxidoreductase (NQO1) is a cytosolic enzyme
that catalyzes two-electron reduction of quinones, with NADH/
NADPH as electron donors. NQO1 expression is induced in
response to a variety of signals including oxidants and ionizing
radiation. A C609T substitution, encoding for a Pro187Ser amino
acid change is the major NQO1 polymorphism described. This
polymorphic variant possesses less than 4% of the wild-type
enzymatic activity and is associated with increased risk of developing
different types of tumors [21–23]. Recently, ornithine decarboxylase,
p33
ING1b, p53 and p73 were found to be degraded by 20S
proteasomes and NQO1 was shown to inhibit this degradation
[24–29]. The finding that NQO1 supports the accumulation of p53
attributes to NQO1 a role as a tumor suppressor.
Due to the structural similarities between p53 and p63, it seemed
plausible that NQO1 also regulates p63 expression. Our study tests
this idea. We have chosen to focus on TAp63c, as it is the most
potent transcription activator and it is expected to have a role in
tumor suppression. Our data demonstrate that wild-type but not
C609T NQO1 binds to, stabilizes and inhibits 20S proteasomal
degradation of TAp63c. We further show that downregulation of
NQO1inhibitsTAp63c-dependant p21upregulationandTAp63c-
induced growth arrest stimulated by doxorubicin. These findings
provide insight into the contribution of NQO1 to p63 stability.
Materials and Methods
Cell lines
HCT116 (kindly provided by Prof. Yossi Shaul, Weizmann
Institute of Science, Israel), HCT116
2/2 (kindly provided by Prof.
Moshe Oren, Weizmann Institute of Science, Israel), HEK293
cells (kindly provided by Prof. Yehiel Zick, Weizmann Institute of
Science, Israel) were maintained in DMEM supplemented with
10% serum, 2mM glutamine, penicillin/streptomycin and cul-
tured at 37uC in a humidified incubator with 5% CO2.
Compounds
Doxorubicin (DOX) (Sigma) was dissolved in H2O; 1mM was
added to the cells, unless stated otherwise. The proteasome
inhibitor, MG132 (Sigma), was dissolved in DMSO. Cyclohex-
amide (Sigma), 10mg/ml was added to the cells.
Plasmids and cloning
Wild-type NQO1 (GenBank accession no. J03934) was cloned
into an HA-pCDNA3 expression vector. C609T NQO1 was
generated using the QuikChange site-directed mutagenesis kit
according to the manufacturer’s instructions (Stratagene) with
appropriate primers:
Sense: 59-GTGGCTTCCAAGTCTTAGAATCTCAACTGA-
CATATAGC-39.
Anti-sense: 59-GCTATATGTCAGTTGAGATTCTAAGAC-
TTGGAAGCCAC-39.
Flag-tagged NQO1 expression vector was kindly provided by
Prof. Yosef Shaul, Weizmann Institute of Science, Israel. TAp63c
expression vector was kindly provided by Prof. Kurt Engeland,
University of Leipzig, Germany.
siRNA transfections
siRNA oligonucleotides targeting NQO1 or scrambled oligo-
nucleotides (Ambion) were transfected using siPORT NeoFX
(Ambion) following manufacturer’s guidelines. After 24h, cells
were transfected with TAp63c as described below, and incubated
for an additional 24h before being harvested.
Transfections
Transfections of TAp63c and NQO1 expression plasmids were
performed using jetPEI transfection reagent (Polyplus-transfec-
tion), following manufacturer’s guidelines. Briefly: Cells were
seeded in 6-well plates 24h before transfection. JetPEI was mixed
with each plasmid and complex formation was allowed to take
place for 20 min at room temperature before being added to the
wells. Cells were harvested 48h later, as described below. Stable
transfection of HA-NQO1 in 293 cells was performed in the same
manner followed by neomycin-selection. Neomycin-resistant
colonies expressing HA-NQO1 were identified by immunoblot
analysis with anti-HA antibody.
Western blot
Cells were harvested using lysis buffer (50mM Tris-HCl pH 7.4,
150mM NaCl, 1mM EDTA, 1% TRITON X-100 and protease
inhibitor cocktail). Equal amounts of protein were separated by
10% SDS-PAGE and blotted onto PVDF membranes. Mem-
branes were blocked over night at 4uC and probed with the
appropriate primary for 1h at room temperature and then with the
appropriate fluorescently-labeled secondary antibody (Li-Cor
Biosciences). Membranes were scanned using ODYSSEY Infrared
Imaging System (Li-Cor Biosciences). Primary antibodies used:
NQO1, p63 (4A4), GAPDH (Santa Cruz Biotechnology); HA
(Covance); FLAG (Sigma).
For stabilization experiments, cells were transfected with
TAp63c and NQO1 expression plasmids as described above.
Twenty-four hours after the transfections, the cells were treated
with 10mg/ml cyclohexamide for 4h. Cells were then collected and
analyzed by Western blot analysis as described.
Real-time PCR
RNA was isolated using RNAqueous-4PCR kit (Ambion) and
reverse transcribed using the high capacity cDNA RT kit
(Ambion). Real-time PCR was then performed using the SDS
7000 machine (Applied Biosystems) in a 20ml reaction containing
40ng RNA, 10ml TaqMan master mix (Ambion), 1ml of target gene
or 18S rRNA control primers and a FAM dye-labeled TaqMan
probe (Ambion). Amplification conditions were: 50uC for 2 min,
followed by 95uC for 10 min, then 40 cycles of 95uC for 15 sec
and 60uC for 1 min. The DDCt method was used to calculate
relative expression levels.
Reverse transcription (RT)-PCR
RNA was extracted using Nucleospin RNA II kit (Macherey-
Nagel) and reverse transcribed with RevertAid M-MuLV (Fermen-
tas). PCR reactions were performed using TAp63 primers and
gapdh control primers. TAp63 PCR products were separated on
agarose gels and their intensity was calculated relative to the gapdh
PCR products, using ImageJ. Primers used: TAp63 forward 59-
TCGTAGAAACCCCAGCTCAT-39; reverse 59-TTGTTTGTC-
GCACCATCTTC-39. gapdh forward 59-ACCACAGTCCAT-
GCCATCAC-39; reverse: 59-CCACCACCCTGTTGCTGTA-39.
Cell cycle analysis
Cells were transfected with either siNQO1 oligonucleotides or
scrambled oligonucleotides. Twenty-four hours following this
transfection, the cells were transfected with a TAp63c expression
plasmid (as described above). Cells were treated with 0.05mM DOX
24h after the transfections. Following an additional 24h, the cells
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prepared for analysis using a detergent-trypsin method followed by
staining with propidium-iodide [30]. DNA content was analyzed by
FACSCALIBUR (Becton Dickinson), using ModFitLT cell cycle
analysis software (Verity Software House Inc.).
Co–immunoprecipitation
Immunoprecipitation (IP) was carried out using the ExactaCruz
product (Santa Cruz Biotechnology) following manufacturer’s
guidelines. Briefly, Cells were transfected with TAp63c and
NQO1 expression plasmids, as described above. Following 48h,
cells were lysed with 500ml lysis buffer (50mM Tris-HCl pH 7.4,
150mM NaCl, 1mM EDTA, 1% TRITON X-100 and protease
inhibitor cocktail) and immunoprecipitated with Exactacruz IP-
matrix that was previously conjugated to anti–HA or anti-p63
antibodies. Immunoprecipitated samples were Western blot
analyzed using appropriate primary antibodies and the secondary
antibodies supplied by the ExactaCruz product.
In-vitro translation
TAp63c and NQO1 expression plasmids were transcribed and
translated using the TnTH-T7 Coupled Reticulocyte Lysate System
(Promega) and the TranscendH Non-Radioactive Translation
Detection Systems (Promega) for incorporating biotinylated lysine
residues into proteins during translation, as described by the supplier.
One ml TranscendH tRNA and 1mg of plasmid DNA were routinely
used in a 50ml assay. Reactions were incubated at 30uCf o r9 0m i n .
In-vitro protein degradation assays
Degradation of in-vitro translated, biotin-labeled p63 with 1mgo f
purified 20S proteasome (ABR-Affinity BioReagents) was carried
out in degradation buffer (100mM Tris-HCL (pH 7.5), 150mM
NaCl, 5mMMgCl, 2mMDTT), with or without in-vitro translated,
biotin-labeled NQO1 and 1mM NADH, at 37uC for 4h. Samples
were then electrophoresed on SDS-PAGE and transferred to PVDF
membranes. Membranes were incubated with fluorescently-labeled
streptavidin for 30 min at room temperature and scanned using
ODYSSEY Infrared Imaging System (Li-Cor Biosciences).
Statistics
Experiments were done in triplicates. Student’s t-test was used
where indicated. p,0.05 was considered significant.
Results
Wild-type but not C609T NQO1 stabilizes TAp63c
expression
The observation that NQO1 stabilizes p53 raised the question
whether NQO1 also participates in dictating p63 expression level.
To clarify this issue, we cotransfected FLAG-tagged NQO1 and
TAp63c expression plasmids into HCT116 and 293 cells. Both
these cell lines do not express detectable levels of endogenous
TAp63c (Fig. 1A). As predicted, both HCT116 and 293 cells over-
expressing NQO1 showed an increase in TAp63c protein level
(Fig. 1A). In order to test whether TAp63c stabilization by NQO1
is dependent on p53, these transfections were also conducted in
p53 null, HCT116
2/2 cells. These cells do not express detectable
levels of endogenous TAp63c either (Fig. 1A). Once again, NQO1
over-expression resulted in elevated TAp63c protein levels,
suggesting that this effect is independent of the cell’s p53 status
(Fig. 1A). In order to confirm that NQO1 indeed prolongs
TAp63c stability, the degradation rate of TAp63c in HCT116
cells treated with cyclohexamide was compared to that of TAp63c
in the presence of NQO1 in HCT116 cells treated with
cyclohexamide. TAp63c levels decreased significantly following
cyclohexamide treatment and by 4 hours were nearly down to
20% compared with non-treated cells (Fig. 1B compare lanes 1, 2).
In contrast, the level of TAp63c in the presence of NQO1 was
only moderately decreased, to 60%, following cyclohexamide
treatment compared with non-treated cells (Fig. 1B compare lanes
3, 4). Similar results were documented in HCT116
2/2 cells, once
again implying that this effect is independent of the cell’s p53
status (data not shown). No upregulation was observed in TAp63c
mRNA level under these conditions in 293 and HCT116
2/2 cells.
A slight upregulation in TAp63c mRNA expression was detected
in HCT116 cells (Fig. 1C). To determine whether the enzymatic
activity of NQO1 is required for p63 stability, we transfected an
HA-tagged C609T NQO1 expression plasmid into all 3 cell lines.
Unlike wild-type NQO1, C609T NQO1 did not stabilize
cotransfected TAp63c (Fig. 1D). Of note, the expression of
transfected C609T NQO1 in these cells was lower than that of
transfected wild-type NQO1 (Fig. 1A and 1D, middle panels).
Continuous attempts to increase C609T NQO1 expression level,
in transient and even in stably transfected lines, failed. This is
possibly due to the fact that the mutant protein is considered to be
unstable [31]. In a paper published by Traver et al [32], the
specific activity of C609T NQO1 purified protein from E. coli cells
was 2% of the specific activity of the wild-type recombinant
protein probably due to diminished ability to bind FAD. The
authors state however that according to their data an additional
possible reason for the lack of enzymatic activity could be to be
due to very poor expression of the C609T NQO1 protein. These
data therefore indicate that TAp63c is stabilized by NQO1 and
that NQO1 enzymatic activity may be required for this.
Effect of NQO1 silencing on TAp63c stability
Dicumarol is a common NQO1 inhibitor. However, dicumarol
was shown to be nonspecific, inhibiting several quinone reductases
and having many ancillary effects [33,34]. Consequently, we
decided to inhibit NQO1 by using NQO1 specific siRNA
molecules. HCT116 and 293 cells were transfected with siNQO1
oligonucleotides or with scrambled oligonucleotides and with a
TAp63c expression plasmid. Expression of NQO1 mRNA and
protein, in the presence of siNQO1, was reduced by an average of
99% and .60% as detected by real-time PCR and Western blot,
respectively (data not shown and Fig. 1E). In both cell lines,
reduction in NQO1 caused a decrease in TAp63c expression
(Fig. 1E). A similar outcome of NQO1 silencing on p63 expression
level was observed in HCT116
2/2 cells, suggesting once again,
that this effect is independent of the cell’s p53 status (Fig. 1E).
These data indicate that decreased NQO1 expression leads to
downregulation of TAp63c.
TAp63c stabilization by NQO1 is enhanced under stress
Under normal growth conditions, TAp63c protein level is
elevated in cells over-expressing NQO1 (Fig. 1A). p63 expression
is known to be induced following stress [35]. At this point, we were
interested in determining the effect of NQO1 on TAp63c
following stress. To this end, cells co-transfected with TAp63c
and NQO1 expression plasmids were treated with DOX. We
show that the stabilizing effect of NQO1 on TAp63c was more
prominent after induction of stress by DOX exposure (Fig. 2). In
contrast, C609T NQO1 did not lead to elevated expression of
TAp63c following DOX treatment (data not shown). These
findings suggest that NQO1 stabilizes TAp63c to a higher extent
in stressed cells as compared to unstressed cells and that NQO1
enzymatic activity may be required for this.
Stabilization of p63 by NQO1
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TAp63c
To detect a potential physical association between TAp63c
and NQO1, 293 cells stably expressing HA-NQO1 were
transfected with a TAp63c expression plasmid. Fig. 3A demon-
strates that immunoprecipitation of HA-NQO1 pulled down
TAp63c (lane 1–2). In agreement, immunoprecipitation of
TAp63c pulled down HA-NQO1 (lane 5–6). Conversely,
immunoprecipitation of C609T NQO1 did not pull down this
p63 isoform under the same conditions (Fig. 3A, lanes 3–4).
These data confirm that TAp63c and NQO1 do interact
physically and that this interaction may be dependent on the
catalytic activity of NQO1.
NQO1 protects TAp63c from 20S proteasomal
degradation
To study whether NQO1 protects TAp63c from degradation, an
in-vitro degradation assay was performed. In this assay, in-vitro
translated TAp63c was used as a substrate for degradation by 20S
proteasomes in the absence or presence of in-vitro translated
NQO1. As has previously been shown for p53 and p73 [26–29],
TAp63c was degraded by 20S proteasomes. This degradation was
inhibited in the presence of excess NQO1 and its cofactor, NADH,
suggesting that NQO1 directly protects TAp63c from degradation
by 20S proteasomes (Fig. 3B). Unlike wild-type NQO1, C609T
NQO1 did not inhibit this degradation (data not shown). It should
be noted that the expression level of C609T NQO1 in the presence
of 20S proteasomes was very low compared to wild-type NQO1. It
is impossible to establish, at this point, whether the absence of
inhibition of TAp63c degradation by C609T NQO1 was due to the
incompetence of C609T NQO1 or was it merely a result of its low
expression level.
Downregulation of NQO1 inhibits TAp63c-mediated
growth arrest
We next determined whether NQO1-dependant TAp63c
accumulation could initiate growth arrest or apoptosis. In order
to neutralize the effect of p53, p53 null HCT116
2/2 cells were
Figure 1. TAp63c protein is stabilized by NQO1. (A) 293, HCT116 and HCT116
2/2 cells expressing endogenous NQO1 or over-expressing wild-
type FLAG-NQO1 were transfected with a plasmid expressing TAp63c. Forty-eight hours post-transfection cell lysates were prepared and resolved by
SDS-PAGE. TAp63c, NQO1 and GAPDH levels were detected by Western blot analysis using anti-p63 (4A4), anti-FLAG and anti-GAPDH (loading
control) antibodies, respectively. (B) HCT116 cells expressing endogenous NQO1 or over-expressing wild-type FLAG-NQO1 were transfected with a
plasmid expressing TAp63c. Twenty-four hours post transfection, 10mg/ml cyclohexamide (CHX) was added for 4 hours. Cell lysates were prepared
and resolved by SDS-PAGE. TAp63c, NQO1 and GAPDH levels were detected by Western blot analysis using anti-p63 (4A4), anti-FLAG and anti-GAPDH
(loading control) antibodies, respectively. (C) RNA was prepared from these same cells, reverse transcribed and RT-PCR was performed using primers
specific for TAp63 and for gapdh. Data is represented as relative levels of TAp63c normalized to gapdh. (D) 293, HCT116 and HCT116
2/2 cells were
co-transfected with plasmids expressing TAp63c and HA-C609T NQO1. Forty-eight hours post-transfection cell lysates were prepared and resolved by
SDS-PAGE. TAp63c, NQO1 and GAPDH levels were detected by Western blot analysis using anti-p63 (4A4), anti-HA and anti-GAPDH (loading control)
antibodies, respectively. (E) 293, HCT116 and HCT116
2/2 cells were transfected with scrambled oligonucleotides or siNQO1 oligonucleotides. Twenty-
four hours post-transfection cell were transfected with a plasmid expressing TAp63c. Twenty-four hours post-transfection cell lysates were prepared
and resolved by SDS-PAGE. TAp63c, NQO1 and GAPDH levels were detected by Western blot analysis using anti-p63 (4A4), anti-NQO1 and anti-
GAPDH (loading control) antibodies, respectively.
doi:10.1371/journal.pone.0011401.g001
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than apoptosis we tested the effect of NQO1 on TAp63c-mediated
growth arrest. Exposure of HCT116
2/2 cells to DOX resulted in
G2 arrest (Fig. 4C). The presence of TAp63c lead to a slight
increase in G2 arrested cells (Fig. 4D). A 5-fold increase in p21
mRNA expression was also detected in these TAp63c over-
expressing cells exposed to DOX in comparison to cell exposed to
DOX but not expressing TAp63c (Fig. 4I). NQO1 inhibition in
DOX treated, TAp63c transfected cells, resulted in a reduction of
G2 arrested cells to the level observed following DOX in cells not
expressing TAp63c (Fig. 3H). Accordingly, TAp63c and DOX-
mediated increase in p21 level was almost completely reversed by
siNQO1 (Fig. 3I). Expression of TAp63c, without an additional
stress signal, did not lead to cell cycle arrest in our setting. These
results are consistent with our NQO1 overexpression and silencing
data and suggest that NQO1 is an important regulator of TAp63c
and consequently of p21. Our data indicate that downregulation
of NQO1 inhibits TAp63c-mediated p21 upregulation and
TAp63c-induced G2 arrest in DOX treated HCT116
2/2 cells.
Discussion
Similar to p53, TAp63c protein level increases upon treatment
with DNA damaging agents resulting in transactivation of p53-
responsive genes assigning p63 as an important component of the
cell’s apoptotic machinery [35–37]. This p63 upregulation is not
the result of transcriptional activation, but is most likely due to an
increase at the protein level [36,37]. To date, little is known of the
molecular mechanisms regulating p63 protein level. We provide
in-vitro evidence for a physical and functional relationship
between TAp63c and NQO1 supporting a new pathway
regulating p63 stability.
In different types of unstressed cells, wild-type NQO1 bound to
and stabilized TAp63c. In contrast, we show that C609T NQO1
Figure 2. TAp63c expression is stabilized by NQO1 in response to genotoxic stress. 293, HCT116 and HCT116
2/2 cells expressing
endogenous NQO1 or over-expressing wild-type FLAG-NQO1 were transfected with a plasmid expressing TAp63c. Twenty-four hours post-
transfection cells were treated with 1mM DOX for 24h. At this point, cell lysates were prepared and resolved by SDS-PAGE. TAp63c, NQO1 and GAPDH
levels were detected by Western blot analysis using anti-p63 (4A4), anti-FLAG and anti-GAPDH (loading control) antibodies, respectively.
doi:10.1371/journal.pone.0011401.g002
Figure 3. NQO1 physically associates with TAp63c and protects it from 20S proteasomal degradation. (A) 293 cells stably expressing
HA-NQO1 or HA-C609T NQO1 were transfected with a plasmid expressing TAp63c. Cellular extracts were prepared and subject to
immunoprecipitated (IP) with anti-HA or anti-p63 antibodies. Immunoprecipitated proteins and 5% of input material were detected by Western
blot using anti-p63 and anti-HA antibodies. (B) Degradation of in-vitro translated, biotin-labeled TAp63c with 20S proteasome was carried out in the
presence or absence of in-vitro translated, biotin-labeled NQO1 and 1mM NADH at 37uC for 4h. Biotin-labeled TAp63c and NQO1 were detected with
fluorescently-labeled streptavidin.
doi:10.1371/journal.pone.0011401.g003
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This observation emphasizes the requirement of proper NQO1
enzymatic activity for p63 stabilization. It remains to be
determined whether intact enzymatic activity of NQO1 and its
binding to TAp63c is sufficient for p63 stabilization. NQO1 did
not alter the expression of GAPDH or retinoblastoma (data not
shown for retinoblastoma) implying that this protein degradation
regulatory pathway is specific to certain proteins.
p63 has been shown to undergo ITCH mediated 26S
proteasome degradation [16]. Our results show that, in addition,
TAp63c is subjected to 20S proteasomal degradation and that
NQO1 protects TAp63c from such degradation. This finding
implies that p63 stabilization may involve several parallel
mechanisms.
Many evidence support the notion that p63 has tumor
suppressor functions: 1) p63 specific siRNA enhances the
transformation potential of p53
2/2 MEFs [38]; 2) p63 can
mediate chemo-sensitivity independent of p53 status by induction
of apoptosis [17,39]; 3) The combined absence of p63 and p73
severely impairs the induction of p53-dependent apoptosis in
response to DNA damage [40]. These observations suggest that
p63 may complement, and in some circumstances substitute for
Figure 4. Downregulation of NQO1 inhibits TAp63c-dependent growth arrest in DOX treated HCT116
2/2 cells. HCT116
2/2 cells were
transfected with scrambled oligonucleotides (siControl) (A–D) or siNQO1 oligonucleotides (E–H) and transfected (B, D, F, H) or not (A, C, E, G) with a
plasmid expressing TAp63c. Twenty-four hours post-transfection the cells were treated or not with 0.05mM DOX. 24h after this treatment, DNA
content was analyzed by propidium-iodide staining. The percentage of cells in G1 and G2 is presented. (I) RNA was prepared from these same cells,
reverse transcribed and real time PCR was performed using primers specific for p21 and 18S rRNA. Data is represented as relative levels of p21
normalized to 18S rRNA. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0011401.g004
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regulate the expression of the p63 isoforms. Phosphorylation has
been reported to be associated with rapid accumulation of
TAp63c upon genotoxic treatment whereas DNp63a is degraded
under these same conditions [15]. Coherently, in our settings,
NQO1 over-expression accompanied by stress (DOX) resulted in
the accumulation of TAp63c and not in the accumulation of the
antagonizing DN isoforms or the weak TAp63c (data not shown).
Stabilization of TAp63c by NQO1 is of biological relevance since
the ability of TAp63c to upregulate p21 and to induce G2 arrest in
stressed HCT116
2/2 cells is almost abolished in the presence of
siNQO1.
Our results have biological implications concerning the
understanding of tumor development. Cells carrying polymorphic
inactive NQO1 that are exposed to carcinogens that are substrate
for detoxification by NQO1 will accumulate more damage than
cells carrying wild-type NQO1. Our results show that polymor-
phic NQO1 does not stabilize TAp63c and low wild-type NQO1
levels (as detected in cells harboring one allele of polymorphic
NQO1) decrease TAp63c-induced growth arrest. These cells,
already harboring damaged DNA, would therefore also exhibit
imperfect apoptotic or growth arrest responses, providing them
with a growth advantage that could potentially lead to tumor
development. Indeed, p63 is not frequently mutated in cancer but
rather alterations of p63 expression have been widely reported
[10–12,41]. Of note, C609T NQO1 is known to enhance
susceptibility to bladder and breast cancers [21–23]. In these
same tumor types, TAp63 expression is often misregulated [6–8].
The altered TAp63 expression levels detected in these tumors may
be explained by the incompetence of C609T NQO1 to properly
stabilize p63. In one study, Fagerholm et al demonstrated that the
chemotherapeutic response of C609T homozygous breast carci-
noma cells was impaired in p53-aberrant tumors [21]. This
phenomenon could be attributed to the inability of polymorphic
NQO1 to stabilize TAp63, whose expression was indeed shown to
be significantly reduced in breast cancers. TAp63 reduction could
result in the poor chemotherapeutic response characteristic of
these tumor cells.
Our report is the first to identify a new mechanism appointing a
direct role for NQO1 in the regulation of p63 expression,
especially following stress. We propose that NQO1 associates with
and stabilizes TAp63c. The increase in TAp63c results in
enhanced transcription of p21 consequently leading to growth
arrest. Characterization of the interactions between NQO1 and
the other p63 family members would be an interesting future
study. Such studies will probably elucidate that NQO1 not only
regulates the expression of the potent TAp63c but more
realistically it regulates the balance of p63 isoforms under normal
growth conditions and following stress. It will be interesting to
explore how this level of regulation collaborates with others as
more regulators of p63 are found. Clearly, comprehension of such
regulations of the p63 isoforms will lead to a greater understanding
of the role of p63 in tumor suppression.
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